Literature DB >> 20805428

Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan.

Fang-I Hsieh1, Li-Ming Lien, Sien-Tsong Chen, Chyi-Huey Bai, Mu-Chien Sun, Hung-Pin Tseng, Yu-Wei Chen, Chih-Hung Chen, Jiann-Shing Jeng, Song-Yen Tsai, Huey-Juan Lin, Chung-Hsiang Liu, Yuk-Keung Lo, Han-Jung Chen, Hou-Chang Chiu, Ming-Liang Lai, Ruey-Tay Lin, Ming-Hui Sun, Bak-Sau Yip, Hung-Yi Chiou, Chung Y Hsu.   

Abstract

BACKGROUND: Stroke is a leading cause of death around the world. Improving the quality of stroke care is a global priority, despite the diverse healthcare economies across nations. The American Heart Association/American Stroke Association Get With the Guidelines-Stroke program (GWTG-Stroke) has improved the quality of stroke care in 790 US academic and community hospitals, with broad implications for the rest of the country. The generalizability of GWTG-Stroke across national and economic boundaries remains to be tested. The Taiwan Stroke Registry, with 30 599 stroke admissions between 2006 and 2008, was used to assess the applicability of GWTG-Stroke in Taiwan, which spends ≈ 1/10 of what the United States does in medical costs per new or recurrent stroke. METHODS AND
RESULTS: Taiwan Stroke Registry, sponsored by the Taiwan Department of Health, engages 39 academic and community hospitals and covers the entire country with 4 steps of quality control to ensure the reliability of entered data. Five GWTG-Stroke performance measures and 1 safety indicator are applicable to assess Taiwan Stroke Registry quality of stroke care. Demographic and outcome figures are comparable between GWTG-Stroke and Taiwan Stroke Registry. Two indicators (early and discharge antithrombotics) are close to GWTG-Stroke standards, while 3 other indicators (intravenous tissue plasminogen activator, anticoagulation for atrial fibrillation, lipid-lowering medication) and 1 safety indicator fall behind. Preliminary analysis shows that compliance with selected GWTG-Stroke guidelines is associated with better outcomes.
CONCLUSIONS: Results suggest that GWTG-Stroke performance measures, with modification for ethnic factors, can become global standards across national and economic boundaries for assessing and improving quality of stroke care and outcomes. GWTG-Stroke can be incorporated into ongoing stroke registries across nations.

Entities:  

Mesh:

Year:  2010        PMID: 20805428     DOI: 10.1161/CIRCULATIONAHA.110.936526

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  103 in total

1.  A comprehensive stroke center patient registry: advantages, limitations, and lessons learned.

Authors:  James E Siegler; Amelia K Boehme; Adrianne M Dorsey; Dominique J Monlezun; Alex J George; Amir Shaban; H Jeremy Bockholt; Karen C Albright; Sheryl Martin-Schild
Journal:  Med Student Res J       Date:  2013-05-31

2.  Adherence to American Heart Association/American Stroke Association Clinical Performance Measures in a Peruvian Neurological Reference Institute.

Authors:  Carlos Abanto; Angela K Ulrich; Ana Valencia; Víctor Dueñas; Silvia Montano; David Tirschwell; Joseph Zunt
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-09-09       Impact factor: 2.136

3.  Suboptimal lipid management before and after ischaemic stroke and TIA-the North Dublin Population Stroke Study.

Authors:  Danielle Ní Chróinín; Chantelle Ní Chróinín; Layan Akijian; Elizabeth L Callaly; Niamh Hannon; Lisa Kelly; Michael Marnane; Áine Merwick; Órla Sheehan; Gillian Horgan; Joseph Duggan; Lorraine Kyne; Eamon Dolan; Seán Murphy; David Williams; Peter J Kelly
Journal:  Ir J Med Sci       Date:  2018-01-24       Impact factor: 1.568

4.  PPAR-γ Ameliorates Neuronal Apoptosis and Ischemic Brain Injury via Suppressing NF-κB-Driven p22phox Transcription.

Authors:  Jui-Sheng Wu; Hsin-Da Tsai; Wai-Mui Cheung; Chung Y Hsu; Teng-Nan Lin
Journal:  Mol Neurobiol       Date:  2015-06-25       Impact factor: 5.590

5.  Outcomes of acute cardiovascular events in rheumatoid arthritis and systemic lupus erythematosus: a population-based study.

Authors:  Chao-Han Lai; Cheng-Yang Hsieh; April Barnado; Li-Ching Huang; Sheau-Chiann Chen; Liang-Miin Tsai; Yu Shyr; Chung-Yi Li
Journal:  Rheumatology (Oxford)       Date:  2020-06-01       Impact factor: 7.580

6.  Applying density-based outlier identifications using multiple datasets for validation of stroke clinical outcomes.

Authors:  Ching-Heng Lin; Kai-Cheng Hsu; Kory R Johnson; Marie Luby; Yang C Fann
Journal:  Int J Med Inform       Date:  2019-10-03       Impact factor: 4.046

7.  The functional role of hemojuvelin in acute ischemic stroke.

Authors:  Guang-Huar Young; Sung-Chun Tang; Vin-Cent Wu; Kuo-Chuan Wang; Jing-Yi Nong; Po-Yuan Huang; Chaur-Jong Hu; Hung-Yi Chiou; Jiann-Shing Jeng; Chung Y Hsu
Journal:  J Cereb Blood Flow Metab       Date:  2019-07-15       Impact factor: 6.200

8.  Utilization of emergency medical service increases chance of thrombolytic therapy in patients with acute ischemic stroke.

Authors:  Ming-Ju Hsieh; Sung-Chun Tang; Wen-Chu Chiang; Kuang-Yu Huang; Anna Marie Chang; Patrick Chow-In Ko; Li-Kai Tsai; Jiann-Shing Jeng; Matthew Huei-Ming Ma
Journal:  J Formos Med Assoc       Date:  2013-12-02       Impact factor: 3.282

9.  Evaluation of machine learning methods to stroke outcome prediction using a nationwide disease registry.

Authors:  Ching-Heng Lin; Kai-Cheng Hsu; Kory R Johnson; Yang C Fann; Chon-Haw Tsai; Yu Sun; Li-Ming Lien; Wei-Lun Chang; Po-Lin Chen; Cheng-Li Lin; Chung Y Hsu
Journal:  Comput Methods Programs Biomed       Date:  2020-02-01       Impact factor: 5.428

Review 10.  From Data to Action: Neuroepidemiology Informs Implementation Research for Global Stroke Prevention and Treatment.

Authors:  George A Mensah; Ralph L Sacco; Barbara G Vickrey; Uchechukwu K A Sampson; Salina Waddy; Bruce Ovbiagele; Jeyaraj Durai Pandian; Bo Norrving; Valery L Feigin
Journal:  Neuroepidemiology       Date:  2015-10-28       Impact factor: 3.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.